Two Phase II studies demonstrated potential for pazopanib as a single
agent treatment for early stage non-small cell lung cancer and advanced
renal cell cancer:
-- In patients with stage I-III non-small cell lung cancer, 86 percent of
patients who received pazopanib monotherapy experienced a reduction in
-- In patients with advanced renal cell cancer, there was an overall
response rate of 35 percent. The median duration of response was longer
than 16 months (68 weeks) and the median progression-free survival was
LONDON and PHILADELPHIA, May 31 /PRNewswire-USNewswire/ -- GlaxoSmithKline today announced the results of two Phase II trials demonstrating the potential for pazopanib, an oral, investigational angiogenesis inhibitor, as a treatment for non-small cell lung cancer (NSCLC),(1) the most common form of lung cancer,(2) and renal cell carcinoma (RCC).(3) The data were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Pazopanib is not approved in any market for any indication at this time.
Pazopanib targets vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) and c-kit, key proteins that help with the growth of new blood vessels in the body.(4) This process, known as angiogenesis, plays a critical role in the growth and spread of tumors(5).
"These very promising results highlight the potential of pazopanib as a future treatment option across multiple forms of cancer," said Thierry Le Chevalier, M.D., Vice President, Oncology Medicine Development Center, GSK. "GSK is conducting a broad research program for pazopanib in a number of tumor types and this demonstrates our ongoing commitment to the development of innovative and effective treatments for patients with cancer."
Pazopanib and Non-Small Cell Lung Cancer: abstract 7557 (1)
Copyright©2008 PR Newswire.
All rights reserved